Loading clinical trials...
Loading clinical trials...
Recent reports have identified a specific oncogenic mutation L265P of the MYD88 gene in approximately 30% of the patients with the activated B-cell (ABC) type of Diffuse Large B Cell Lymphoma (DLBCL)....
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Idera Pharmaceuticals, Inc.
NCT07260812 · Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
NCT05006716 · B-cell Malignancy, Marginal Zone Lymphoma, and more
NCT06026319 · Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, and more
NCT07368270 · Diffuse Large B Cell Lymphoma
NCT07288879 · DLBCL - Diffuse Large B Cell Lymphoma, CAR T Cell Therapy
UCLA Medical Center
Los Angeles, California
Emory University
Atlanta, Georgia
Cancer Care Specialists of Illinois
Decatur, Illinois
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions